Natasha Rekhtman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/383426/publications.pdf

Version: 2024-02-01

143	23,691	25034	11308
papers	citations	57 h-index	136 g-index

146	146	146	26271
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung. Cancer Discovery, 2022, 12, 562-585.	9.4	48
2	Lung neuroendocrine neoplasms: recent progress and persistent challenges. Modern Pathology, 2022, 35, 36-50.	5.5	74
3	The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. Journal of Thoracic Oncology, 2022, 17, 362-387.	1.1	429
4	The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. Nature Communications, 2022, 13, 1450.	12.8	47
5	Defining Novel DNA Virus-Tumor Associations and Genomic Correlates Using Prospective Clinical Tumor/Normal Matched Sequencing Data. Journal of Molecular Diagnostics, 2022, 24, 515-528.	2.8	12
6	CT-based Radiogenomic Analysis of Clinical Stage I Lung Adenocarcinoma with Histopathologic Features and Oncologic Outcomes. Radiology, 2022, 303, 664-672.	7.3	28
7	NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2022, 17, 793-805.	1.1	6
8	Molecular Testing Identifies Ultra-Late Recurrences in Lung Carcinomas: Implications for Clinical Management. Journal of Thoracic Oncology, 2022, 17, e50-e51.	1.1	0
9	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. British Journal of Cancer, 2022, 126, 889-898.	6.4	8
10	Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts. Nature Communications, 2022, 13, 2144.	12.8	18
11	Clinical outcomes of immune checkpoint inhibitors in HER2-amplified non-small cell lung cancers.. Journal of Clinical Oncology, 2022, 40, e21098-e21098.	1.6	1
12	POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC. Journal of Thoracic Oncology, 2022, 17, 1109-1121.	1.1	29
13	AKT inhibition as a therapeutic strategy to constrain histological transdifferentiation in EGFR-mutant lung adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, e21166-e21166.	1.6	0
14	Expression of novel neuroendocrine markers in breast carcinomas: a study of INSM1, ASCL1, andÂPOU2F3. Human Pathology, 2022, 127, 102-111.	2.0	4
15	Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset. Clinical Cancer Research, 2022, 28, 4702-4713.	7.0	25
16	Percutaneous computed tomography guided biopsy of sub-solid pulmonary nodules: differentiating solid from ground glass components at the time of biopsy. Clinical Imaging, 2021, 69, 332-338.	1.5	7
17	A Performance Comparison of Commonly Used Assays to Detect RET Fusions. Clinical Cancer Research, 2021, 27, 1316-1328.	7.0	39
18	MET Exon 14â€“altered Lung Cancers and MET Inhibitor Resistance. Clinical Cancer Research, 2021, 27, 799-806.	7.0	35

#	Article	IF	Citations
19	A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma. JAMA Surgery, 2021, 156, e205601.	4.3	52
20	Are there imaging characteristics that can distinguish separate primary lung carcinomas from intrapulmonary metastases using next-generation sequencing as a gold standard?. Lung Cancer, 2021, 153, 158-164.	2.0	4
21	Rapid EGFR Mutation Detection Using the Idylla Platform. Journal of Molecular Diagnostics, 2021, 23, 310-322.	2.8	19
22	Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1-rearranged lung cancers.. Journal of Clinical Oncology, 2021, 39, 9049-9049.	1.6	0
23	Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes. Clinical Cancer Research, 2021, 27, 4066-4076.	7.0	45
24	Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation. Cancer Discovery, 2021, 11, 3028-3047.	9.4	66
25	Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers. JTO Clinical and Research Reports, 2021, 2, 100187.	1.1	11
26	Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers. Journal of Thoracic Oncology, 2021, 16, 1149-1165.	1.1	18
27	The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer. Cancers, 2021, 13, 3656.	3.7	8
28	Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling. Journal of Thoracic Oncology, 2021, 16, 1188-1199.	1.1	23
29	Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer. Nature Communications, 2021, 12, 4789.	12.8	21
30	Spread Through Air Spaces (STAS) in Nonâ˜Small Cell Lung Carcinoma. American Journal of Surgical Pathology, 2021, 45, 1509-1515.	3.7	14
31	Bronchiolar Adenoma/Pulmonary Ciliated Muconodular Papillary Tumor. American Journal of Clinical Pathology, 2021, 155, 832-844.	0.7	20
32	Identification of Immunohistochemical Reagents for In Situ Protein Expression Analysis of Coronavirus-associated Changes in Human Tissues. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 5-12.	1.2	26
33	Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell, 2021, 39, 1479-1496.e18.	16.8	155
34	Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. Journal of Hematology and Oncology, 2021, 14, 170.	17.0	26
35	Three-Dimensional Histologic, Immunohistochemical, and Multiplex Immunofluorescence Analyses of Dynamic Vessel Co-Option of Spread Through Air Spaces in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2020, 15, 589-600.	1.1	55
36	SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. Journal of Thoracic Oncology, 2020, 15, 231-247.	1.1	172

#	Article	IF	Citations
37	SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. Journal of Thoracic Oncology, 2020, 15, 1823-1835.	1.1	234
38	Multiple faces of pulmonary large cell neuroendocrine carcinoma: update with a focus on practical approach to diagnosis. Translational Lung Cancer Research, 2020, 9, 860-878.	2.8	31
39	Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer. Cell Reports, 2020, 33, 108444.	6.4	118
40	Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. Cancer Cell, 2020, 38, 229-246.e13.	16.8	210
41	The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. Clinical Cancer Research, 2020, 26, 5701-5708.	7.0	133
42	CNS Metastases in Patients With MET Exon 14â€“Altered Lung Cancers and Outcomes With Crizotinib. JCO Precision Oncology, 2020, 4, 871-876.	3.0	14
43	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1409-1424.	1.1	182
44	The Newly Described Filigree Pattern Is an Expansion of the Micropapillary Adenocarcinoma Concept Rather Than a Proposed New Subtype. Journal of Thoracic Oncology, 2020, 15, e121-e124.	1.1	5
45	MET-dependent solid tumours â€” molecular diagnosis and targeted therapy. Nature Reviews Clinical Oncology, 2020, 17, 569-587.	27.6	165
46	Insights into pathogenesis of fatal COVIDâ€19 pneumonia from histopathology with immunohistochemical and viral RNA studies. Histopathology, 2020, 77, 915-925.	2.9	92
47	Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e435-e444.	2.6	46
48	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1599-1610.	1.1	234
49	Spread Through Air Spaces Is Prognostic in Neuroendocrine Lung Tumors and Can Be Distinguished From Artifacts. Journal of Thoracic Oncology, 2020, 15, e118-e120.	1.1	6
50	Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma. Modern Pathology, 2020, 33, 2244-2255.	5.5	23
51	Pulmonary sclerosing pneumocytoma: Cytomorphology and immunoprofile. Cancer Cytopathology, 2020, 128, 414-423.	2.4	8
52	Regenerative lineages and immune-mediated pruning in lung cancer metastasis. Nature Medicine, 2020, 26, 259-269.	30.7	274
53	â€œNapoleon Hatâ€•Sign: A Distinctive Cytologic Clue to Reactive Pneumocytes. Archives of Pathology and Laboratory Medicine, 2020, 144, 443-445.	2.5	2
54	Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. Clinical Cancer Research, 2020, 26, 2654-2663.	7.0	230

#	Article	IF	Citations
55	An update on touch preparations of small biopsies. Journal of the American Society of Cytopathology, 2020, 9, 322-331.	0.5	14
56	Ultrarapid EGFR Mutation Screening Followed by Comprehensive Next-Generation Sequencing: AÂFeasible, Informative Approach for Lung Carcinoma Cytology Specimens With a High Success Rate. JTO Clinical and Research Reports, 2020, 1, 100077.	1.1	18
57	Molecular subtypes and clinical outcomes to initial systemic treatment in patients with small cell lung cancer.. Journal of Clinical Oncology, 2020, 38, 9018-9018.	1.6	1
58	YES1 amplification as a primary driver of lung tumorigenesis and YES1/YAP1 amplifications as mediators of acquired resistance (AR) to ALK and EGFR tyrosine kinase inhibitors (TKIs).. Journal of Clinical Oncology, 2020, 38, e21591-e21591.	1.6	0
59	CytoLyt fixation significantly inhibits MIB1 immunoreactivity whereas alternative Kiâ€67 clone 30â€9 is not susceptible to the inhibition: Critical diagnostic implications. Cancer Cytopathology, 2019, 127, 643-649.	2.4	21
60	Concurrent RB1 and TP53 Alterations Define aÂSubset of EGFR-Mutant Lung Cancers at risk forÂHistologic Transformation and Inferior Clinical Outcomes. Journal of Thoracic Oncology, 2019, 14, 1784-1793.	1.1	232
61	Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids. Cancer Research, 2019, 79, 4339-4347.	0.9	47
62	Large No More: The Journey of Pulmonary Large Cell Carcinoma from Common to Rare Entity. Journal of Thoracic Oncology, 2019, 14, 1125-1127.	1.1	21
63	Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. Journal of Thoracic Oncology, 2019, 14, 1583-1593.	1.1	55
64	Expansion of the Concept of Micropapillary Adenocarcinoma to Include a Newly Recognized Filigree Pattern as Well as the Classical Pattern Based on 1468 Stage I Lung Adenocarcinomas. Journal of Thoracic Oncology, 2019, 14, 1948-1961.	1.1	35
65	Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach. Clinical Cancer Research, 2019, 25, 7113-7125.	7.0	69
66	Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma. Clinical Cancer Research, 2019, 25, 7475-7484.	7.0	30
67	Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers. JCO Precision Oncology, 2019, 3, 1-8.	3.0	73
68	Immunostains: Solid Tumors. , 2019, , 23-48.		0
69	Grading (and Classification) Systems Quick Reference: Solid Tumors. , 2019, , 93-111.		0
70	Immunocytochemistry for predictive biomarker testing in lung cancer cytology. Cancer Cytopathology, 2019, 127, 325-339.	2.4	78
71	Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices. Modern Pathology, 2019, 32, 1106-1122.	5.5	58
72	Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. Journal of Physical Education and Sports Management, 2019, 5, a003665.	1.2	23

#	Article	IF	Citations
73	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 377-407.	1.1	212
74	Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)-Positive T1 Lung Adenocarcinoma: AÂPropensity Scoreâ€“Matched Analysis. Journal of Thoracic Oncology, 2019, 14, 87-98.	1.1	153
75	Real-world experience and molecular features of response to immune checkpoint blockade in patients with recurrent small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, 8556-8556.	1.6	2
76	MET inhibitor resistance in patients with MET exon 14-altered lung cancers.. Journal of Clinical Oncology, 2019, 37, 9006-9006.	1.6	24
77	Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers.. Journal of Clinical Oncology, 2019, 37, 9028-9028.	1.6	22
78	Clinicopathologic characteristics of NRG1 fusion-positive cancers: A single-institution study.. Journal of Clinical Oncology, 2019, 37, 3129-3129.	1.6	0
79	Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. Cancer Discovery, 2018, 8, 686-695.	9.4	149
80	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell, 2018, 33, 843-852.e4.	16.8	827
81	Commentary on Testing of Non-Adenocarcinomas. Archives of Pathology and Laboratory Medicine, 2018, 142, 798-798.	2.5	2
82	Interpathologist Diagnostic Agreement for Nonâ€“Small Cell Lung Carcinomas Using Current and Recent Classifications. Archives of Pathology and Laboratory Medicine, 2018, 142, 1537-1548.	2.5	9
83	Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients. Lung Cancer, 2018, 119, 85-90.	2.0	38
84	Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations. Modern Pathology, 2018, 31, 111-121.	5.5	50
85	Novel Modification of HistoGel-Based Cell Block Preparation Method: Improved Sufficiency for Molecular Studies. Archives of Pathology and Laboratory Medicine, 2018, 142, 529-535.	2.5	30
86	Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma. CardioVascular and Interventional Radiology, 2018, 41, 253-259.	2.0	19
87	Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers. JCO Precision Oncology, 2018, 2, 1-12.	3.0	60
88	Molecular Determinants of Response to Antiâ€“Programmed Cell Death (PD)-1 and Antiâ€“Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Nonâ€“Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of Clinical Oncology, 2018, 36, 633-641.	1.6	1,109
89	Prospective Evaluation of Unprocessed Core Needle Biopsy DNA and RNA Yield from Lung, Liver, and Kidney Tumors: Implications for Cancer Genomics. Analytical Cellular Pathology, 2018, 2018, 1-7.	1.4	11
90	Bronchiolar Adenoma. American Journal of Surgical Pathology, 2018, 42, 1010-1026.	3.7	91

#	Article	IF	Citations
91	Type A thymoma presenting with bone metastasis. Histopathology, 2018, 73, 701-703.	2.9	1
92	Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms. Cancer Cytopathology, 2017, 125, 188-196.	2.4	13
93	Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. Cancer Cell, 2017, 31, 286-299.	16.8	370
94	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discovery, 2017, 7, 596-609.	9.4	490
95	Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. Lung Cancer, 2017, 108, 205-211.	2.0	42
96	Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer. Clinical Lung Cancer, 2017, 18, e81-e83.	2.6	1
97	Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancerâ€“Specific Death in Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2017, 12, 223-234.	1.1	134
98	PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. Clinical Cancer Research, 2017, 23, 523-535.	7.0	252
99	Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. PLoS ONE, 2017, 12, e0182665.	2.5	54
100	Cytology Specimens: A Goldmine for Molecular Testing. Archives of Pathology and Laboratory Medicine, 2016, 140, 1189-1190.	2.5	35
101	Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2016, 140, 1267-1272.	2.5	95
102	Molecular Assessment of Multiple Pulmonary Carcinomas: An Evolving Area. Journal of Thoracic Oncology, 2016, 11, e54.	1.1	0
103	Morphologic Accuracy in Differentiating Primary Lung Adenocarcinoma From Squamous Cell Carcinoma in Cytology Specimens. Archives of Pathology and Laboratory Medicine, 2016, 140, 1116-1120.	2.5	22
104	Optimizing Workflows and Processing of Cytologic Samples for Comprehensive Analysis by Next-Generation Sequencing: Memorial Sloan Kettering Cancer Center Experience. Archives of Pathology and Laboratory Medicine, 2016, 140, 1200-1205.	2.5	72
105	Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncology, The, 2016, 17, 1653-1660.	10.7	365
106	Standardized terminology and nomenclature for respiratory cytology: The <scp>P</scp>apanicolaou Society of Cytopathology guidelines. Diagnostic Cytopathology, 2016, 44, 399-409.	1.0	57
107	An Expression Signature as an Aid to the Histologic Classification of Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 4880-4889.	7.0	140
108	Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. Clinical Lung Cancer, 2016, 17, e121-e129.	2.6	116

#	Article	IF	Citations
109	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. Journal of Thoracic Oncology, 2016, 11, 453-474.	1.1	156
110	Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinomaâ€“like and Nonâ€“Small Cell Carcinomaâ€“like Subsets. Clinical Cancer Research, 2016, 22, 3618-3629.	7.0	342
111	Reevaluation and Reclassification of Resected Lung Carcinomas Originally Diagnosed as Squamous Cell Carcinoma Using Immunohistochemical Analysis. American Journal of Surgical Pathology, 2015, 39, 1170-1180.	3.7	61
112	Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping. Cancer Discovery, 2015, 5, 842-849.	9.4	514
113	Nonspecific Reactivity of Polyclonal Napsin A Antibody in Mucinous Adenocarcinomas of Various Sites: A Word of Caution. Archives of Pathology and Laboratory Medicine, 2015, 139, 434-436.	2.5	10
114	Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline. Journal of Oncology Practice, 2015, 11, 135-136.	2.5	20
115	Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases. Cancer Discovery, 2015, 5, 610-621.	9.4	129
116	Mutational landscape determines sensitivity to PD-1 blockade in nonâ€“small cell lung cancer. Science, 2015, 348, 124-128.	12.6	6,756
117	Using frozen section to identify histological patterns in stage I lung adenocarcinoma of â‰¤3Âcm: accuracy and interobserver agreement. Histopathology, 2015, 66, 922-938.	2.9	127
118	Prospective molecular analysis of small cell lung cancer (SCLC) using next generation sequencing (NGS).. Journal of Clinical Oncology, 2015, 33, 7518-7518.	1.6	1
119	Cribriform and fused glands are patterns of high-grade pulmonary adenocarcinoma. Human Pathology, 2014, 45, 213-220.	2.0	73
120	Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline. Journal of Clinical Oncology, 2014, 32, 3673-3679.	1.6	251
121	In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature, 2014, 516, 423-427.	27.8	538
122	Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes. Journal of Thoracic Oncology, 2014, 9, 892-896.	1.1	106
123	Unsuspected Collision of Synchronous Lung Adenocarcinomas: A Potential Cause of Aberrant Driver Mutation Profiles. Journal of Thoracic Oncology, 2014, 9, e1-e3.	1.1	6
124	KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. Modern Pathology, 2013, 26, 1307-1319.	5.5	102
125	Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers. Clinical Cancer Research, 2013, 19, 2240-2247.	7.0	2,097
126	EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics. Molecular Cancer Therapeutics, 2013, 12, 220-229.	4.1	367

#	Article	IF	Citations
127	Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Modern Pathology, 2013, 26, 511-522.	5.5	95
128	Response to Erlotinib in Patients with EGFR Mutant Advanced Nonâ€“Small Cell Lung Cancers with a Squamous or Squamous-like Component. Molecular Cancer Therapeutics, 2012, 11, 2535-2540.	4.1	46
129	Î”Np63 (p40) and Thyroid Transcription Factor-1 Immunoreactivity on Small Biopsies or Cellblocks for Typing Non-small Cell Lung Cancer: A Novel Two-Hit, Sparing-Material Approach. Journal of Thoracic Oncology, 2012, 7, 281-290.	1.1	126
130	ALK-Rearranged Lung Cancer: Adenosquamous Lung Cancer Masquerading as Pure Squamous Carcinoma. Journal of Thoracic Oncology, 2012, 7, 768-769.	1.1	47
131	Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncology, The, 2012, 13, e418-e426.	10.7	178
132	Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations. Clinical Cancer Research, 2012, 18, 1167-1176.	7.0	342
133	p40 (Î”Np63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Modern Pathology, 2012, 25, 405-415.	5.5	343
134	Predicting pulmonary adenocarcinoma outcome based on a cytology grading system. Cancer Cytopathology, 2012, 120, 35-43.	2.4	32
135	Multiplex testing for driver mutations in squamous cell carcinomas of the lung.. Journal of Clinical Oncology, 2012, 30, 7505-7505.	1.6	21
136	Advances in Fine Needle Aspiration Cytology for the Diagnosis of Pulmonary Carcinoma. Pathology Research International, 2011, 2011, 1-7.	1.4	33
137	Subtyping of Non-small Cell Lung Carcinoma: A Comparison of Small Biopsy and Cytology Specimens. Journal of Thoracic Oncology, 2011, 6, 1849-1856.	1.1	121
138	Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Modern Pathology, 2011, 24, 1348-1359.	5.5	299
139	Pathological Diagnosis and Classification of Lung Cancer in Small Biopsies and Cytology: Strategic Management of Tissue for Molecular Testing. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 022-031.	2.1	140
140	Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing. Journal of Thoracic Oncology, 2011, 6, 451-458.	1.1	230
141	Pathologic Diagnosis of Advanced Lung Cancer Based on Small Biopsies and Cytology: A Paradigm Shift. Journal of Thoracic Oncology, 2010, 5, 411-414.	1.1	172
142	Progenitor stem cell marker expression by pulmonary carcinomas. Modern Pathology, 2010, 23, 889-895.	5.5	56
143	Neuroendocrine Tumors of the Lung: An Update. Archives of Pathology and Laboratory Medicine, 2010, 134, 1628-1638.	2.5	355